RESEARCH ARTICLE

Human leukocyte antigen-DQB1 polymorphisms and haplotype patterns in Guillain-Barré syndrome

Shoma Hayat1,2, Israt Jahan1, Avizit Das1, Zahid Hassan3, Zakir Hossain Howlader2, Ishtiaq Mahmud2, Quazi Deen Mohammad4 & Zhahirul Islam1

1Laboratory Sciences and Services Division (LSSD), icddr,b, Dhaka, 1212, Bangladesh
2Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, 1000, Bangladesh
3Department of Physiology and Molecular Biology, Bangladesh, University of Health Sciences (BUHS), Dhaka, 1216, Bangladesh
4National Institute of Neurosciences and Hospital, Dhaka, 1207, Bangladesh

Abstract

Objective: The etiology of Guillain-Barré syndrome (GBS) remains enigmatic, although genetic and environmental factors are speculated to be associated with this autoimmune condition. We investigated whether polymorphisms and the haplotype structures of the human leukocyte antigen (HLA)-DQB1 gene relate to the autoimmune response to infection and affect the development of GBS.

Methods: HLA-DQB1 polymorphic alleles (*0201, *0303, *0304, *0501, *0601) were determined for 151 Bangladeshi patients with GBS and 151 ethnically matched healthy controls using sequence-specific polymerase chain reaction. Pairwise linkage disequilibrium (LD) and haplotype patterns were analyzed based on D statistics and the genotype package in R statistics, respectively. Association studies were conducted using Fisher’s exact test and logistic regression analysis. The Bonferroni method was applied to correct for multiple comparisons, whereby the P-value was multiplied with the number of comparisons and denoted as Pc (Pc, P corrected). Results: No associations were observed between HLA-DQB1 alleles and susceptibility to disease in the comparison between GBS patients and healthy subjects. Haplotype 9 (DQB1*0303–*0601) tended to be less frequent among patients with GBS than healthy controls (P = 0.006, OR = 0.49, 95% CI = 0.30–0.82; Pc = 0.06). Haplotype 5 (DQB1*0301–*0602) and the DQB1*0201 alleles were more frequent in the Campylobacter jejuni-triggered axonal variant of GBS (P = 0.024, OR = 4.06, 95% CI = 1.25–13.18; Pc = 0.24) and demyelinating subtype (P = 0.027, OR = 2.68, 95% CI = 1.17–6.17; Pc = 0.35), though these associations were not significant after Bonferroni correction. Interpretation: This study indicates that HLA-DQB1 polymorphisms are not associated with susceptibility to GBS. In addition, these genetic markers did not influence the clinical features or serological subgroup in patients with C. jejuni-triggered axonal variant of GBS.

Introduction

Guillain-Barré syndrome (GBS) is a postinfectious immune-mediated neuropathy that includes the symptoms of flaccid paralysis. Molecular mimicry between the outer core structures of Campylobacter jejuni and host nerve gangliosides is one apparent cause of GBS, and instigates a tissue-damaging autoimmune response that determines disease presentation.1–5 However, the exact mechanisms that lead to induction of nerve fiber demyelination and axonal damage after antecedent C. jejuni infection remain to be elucidated. Several subtypes of GBS have been associated with specific Campylobacter strains, though a single strain can lead to different subtypes of GBS and only a small percentage (1 in 1000–5000 cases) of patients with C. jejuni enteritis develops GBS.6,7 Thus, molecular mimicry is not the only pathogenic mechanism underlying C. jejuni-triggered GBS.4
Host genetic factors may play a role by modifying regulatory elements that influence GBS susceptibility and disease pathogenesis. In particular, genetic polymorphisms and the resulting haplotype variations may play an important role in the pathogenesis of GBS.

The human leukocyte antigen (HLA) gene complex is extensively polymorphic. The HLA-DQB1 gene, the major stimulus of the DQ antigen, is the most polymorphic HLA variant and also exhibits the most dense linkage disequilibrium (LD). HLA-DQB1 allele variations and haplotype patterns may affect the recognition of self and nonself antigens and have been implicated in the pathology of a number of autoimmune diseases. As one of the most polymorphic regions in the HLA gene complex, HLA-DQB1 has been a focus of inquiry to investigate the genetic and pathophysiological basis of GBS and the associated immune-mediated tissue damage.

Several case-control studies have investigated whether there is an association between HLA class I or II antigens and GBS susceptibility and subgroups. Most of these studies did not find any association or observed weak associations with regard to disease susceptibility to GBS. For example, the DQB1*0602 alleles were significantly associated with increased risk of developing GBS in the Indian population, but no association was found in the Dutch population. One study reported an increased frequency of DQB1*03 alleles among C. jejuni-infected patients with GBS compared to C. jejuni-negative patients, though other studies did not find any association with recent C. jejuni infection. In our view, these differences could be the consequence of limited sample sizes, as well as geographical variations and differences in GBS subtype.

In this study, we used one of the largest cohorts of GBS patients from low/middle-income countries (LMIC) to evaluate the association of HLA-DQB1 polymorphisms with GBS disease susceptibility and the clinical features and serological subgroups of GBS. HLA allele distributions vary between patients with different subtypes of GBS. Therefore, considering the varied regional distribution of HLA alleles and high endemicity and severity of GBS in Bangladesh, we also investigated the association between HLA-DQB1 polymorphic alleles and haplotype patterns with GBS among patients and healthy controls in Bangladesh.

Materials and Methods

Study population

A total of 151 patients with GBS (102 males and 49 females; median age, 29 years [interquartile range, 17–42 years]) diagnosed with GBS at Dhaka Medical College and Hospital (DMCH) using the National Institute of Neurological Disorders and Stroke (NINDS) criteria were enrolled in this study. Patients with GBS were matched with 151 genetically unrelated healthy individuals (77 males and 74 females; median age, 35 years [interquartile range 28–40 years]) without any history of neurological disorders, serious comorbidities (infection, stroke, myocardial infarction, major surgery, etc.), or chronic medical illnesses, with no specific predilection for race, religion, or socioeconomic status during control selection. Written informed consent was obtained from all participants before data collection, clinical examination, and specimen collection. This study was approved by the Institutional Review Board (IRB) and ethics committees of the icddr,b, and Dhaka Medical College and Hospital, Dhaka, Bangladesh.

Peripheral blood and clinical data were collected at entry before treatment for all enrolled patients. The majority of patients with GBS (130/151, 86%) had a history of a preceding illness, either diarrhea (71/130, 55%) or respiratory infection (24/130, 18%) or another preceding illness (35/130, 27%). Electrophysiological studies were performed for 104/151 (69%) patients with GBS; subtype was classified as the axonal type (59/151 [39%]; 55, AMAN and 4, AMSAN); the demyelinating type (27/151, 26%; AIDP), or unclassified GBS with inexcitable nerves or equivocal findings (18/104 [17%]). The severity of disease was assessed at study entry using the medical research council (MRC) sum score at nadir (maximum muscle weakness). Patients with a MRC sum score at nadir of <40 were considered severely affected and between 40 and 60, mildly affected. Disease outcome was measured using the GBS disability score after 6 months follow-up. Antibodies against the C. jejuni and antibodies against GM1, GD1a, and GQ1b gangliosides were measured serologically using enzyme-linked immunosorbent assays (ELISAs).

Genomic DNA isolation

Whole blood was collected from all 302 participants into lithium heparin anticoagulant-coated blood collection tubes for genomic DNA isolation. The QIAamp® DNA Blood Midi Kit (100; Qiagen, Hilden, Germany) was used to isolate genomic DNA according to the manufacturer’s instructions. The eluted DNA samples were dissolved in 1 × TE-buffer (10 mmol/L Tris-Cl, pH 8.0, 1 mmol/L EDTA) and stored at −80°C. DNA samples were diluted in Milli-Q water to a final concentration of 10 ng/µL and stored at −20°C until genotyping.
**HLA typing**

Sequence-specific PCR (PCR-SSP) was performed for HLA-DQB1 typing using previously published primer sequences and reaction conditions. A primer pair was added to each PCR reaction as an internal positive control to amplify the third intron of the DRB1 genes.

**Statistical analysis**

The associations between the HLA-DQB1 alleles and susceptibility to GBS and the clinical or serological features of GBS were assessed using Fisher’s exact test with Yates’ continuity correction and logistic regression analysis. Allele frequencies were reported as P-values, odds ratios (ORs), and 95% confidence intervals (CIs). P-values less than 0.05 were considered statistically significant. HLA-DQB1 allelic frequency was estimated by simple counting and the data were processed using Microsoft Excel 2010 (Microsoft, Redmond, WA), GraphPad Prism (version 5.01, GraphPad software, Inc., La Jolla, CA), and SPSS (16.0 version, Chicago, IL). Pairwise LD was analyzed based on D’ statistics for each of the 13 HLA-DQB1 loci assessed. Haplotype structures and frequencies were estimated from genotypic data and their associations with GBS susceptibility and the clinical and serological subgroups were assessed using logistic regression analysis. Individual alleles with an allele frequency >10% and haplotype frequency >4% within the population were included in the association studies. The Bonferroni method was conducted to correct for multiple comparisons, whereby the P-value was multiplied with the number of comparisons and denoted as Pc (Pc, P corrected).

**Results**

**Influence of HLA-DQB1 polymorphisms and haplotype patterns on GBS susceptibility**

The influence of 13 HLA-DQB1 polymorphic loci on susceptibility to GBS was assessed by comparing patients and healthy controls. No alleles were significantly associated with GBS disease susceptibility (Table 1). However, a trend toward a lower frequency in the DQB1*0601 allele was observed in patients with GBS, but this was not significant when corrections for multiple comparisons were made (P = 0.045, OR = 0.60, 95% CI = 0.38–0.96; Pc = 0.58; Table 1).

In haplotype analysis, a total of 136 different profiles were observed among the two possible combinatorial patterns for the 13 HLA-DQB1 polymorphic loci. Eighty-eight and 90 profiles were observed among the patients with GBS and healthy controls, respectively (Fig. 1). Forty-two profiles were common to both groups, with 46 profiles unique to patients and 44 unique to healthy controls (Fig. 1). Of the 136 haplotype patterns, 10 haplotypes (haplotype 1–10) were predominant (frequency > 4%); these 10 haplotypes represented 64% of total predicted haplotype variation. Haplotype 9 tended to be associated with GBS (DQB1*0303–*0601, P = 0.006, OR = 0.49, 95% CI = 0.30–0.82; P = 0.06; Table 2); no other haplotypes were significantly associated with GBS. Pairwise LD analysis based on D’ statistics indicated significant LD between patients and healthy controls for the *0201–*0302, *0301–*0303, *0301–*0601, *0502–*0503, and *0604–*0605 HLA-DQB1 alleles after correction (Fig. 2).

**Association of HLA-DQB1 polymorphisms with the clinical features and serological subtypes of GBS**

Next, we performed subgroup analysis based on the subtype of GBS and C. jejuni seropositivity (Tables 3 and 4). The DQB1*0201 alleles were significantly more frequent among patients with the demyelinating subtype compared to healthy controls, but this trend was not significant when corrected for multiple comparisons (P = 0.027, OR = 2.68, 95% CI = 1.17–6.17; Pc = 0.35; Table 3). The DQB1*0601 alleles were significantly less frequent among patients with the axonal subtype of GBS compared to healthy controls, but significance was

Table 1. Frequency distribution of HLA-DQB1 polymorphisms in patients with GBS and healthy controls.

| Allele          | GBS   | HC    | P-value | Odds ratio (95% CI) |
|-----------------|-------|-------|---------|---------------------|
| DQB1*0201       | 56 (37) | 48 (32) | 0.397 | 1.26 (0.78–2.03) |
| DQB1*0301/4     | 35 (23) | 37 (25) | 0.893 | 0.92 (0.55–1.58) |
| DQB1*0302       | 63 (42) | 70 (46) | 0.487 | 0.83 (0.53–1.30) |
| DQB1*0303       | 64 (42) | 78 (52) | 0.134 | 0.69 (0.44–1.08) |
| DQB1*0401       | 39 (26) | 27 (18) | 0.125 | 1.60 (0.92–2.78) |
| DQB1*0501       | 31 (21) | 36 (24) | 0.580 | 0.83 (0.48–1.42) |
| DQB1*0502       | 12 (8)  | 21 (14) | 0.139 | 0.53 (0.25–1.12) |
| DQB1*0503       | 20 (13) | 17 (11) | 0.726 | 1.20 (0.60–2.40) |
| DQB1*0601       | 51 (34) | 69 (46) | 0.045 | 0.60 (0.38–0.96) |
| DQB1*0602       | 87 (58) | 81 (54) | 0.562 | 1.17 (0.75–1.85) |
| DQB1*0603/8     | 7 (5)  | 6 (4)  | 1.00   | 1.17 (0.39–3.58) |
| DQB1*0604       | 3 (2)  | 4 (3)  | 1.00   | 0.74 (0.16–3.39) |
| DQB1*0605       | 4 (3)  | 5 (3)  | 1.00   | 0.79 (0.21–3.02) |
| DQB1*03         | 114 (75) | 122 (81) | 0.330 | 0.73 (0.42–1.27) |
| DQB1*05         | 64 (42) | 72 (48) | 0.418 | 0.80 (0.51–1.27) |
| DQB1*06         | 111 (74) | 117 (77) | 0.5    | 0.80 (0.48–1.36) |

GBS, Guillain-Barré syndrome; HC, healthy controls; 95% CI, 95% confidence interval; *Pc = 0.58 (Pc, P corrected).
Figure 1. HLA-DQB1 allelic profiles of patients with GBS and healthy controls. The 136 patterns for the 13 HLA-DQB1 alleles are presented on the right. Green indicates the presence and yellow indicates the absence of specific alleles for the 13 HLA-DQB1 loci. The frequencies of the patterns among patients with GBS and healthy controls are presented as color gradients with the frequencies shown on the left.

Table 2. Logistic regression-derived odd ratios for the associations of predominant haplotype (1–10) with GBS and GM1 autoantibodies.

| Haplotype No. | HLA-DQB1 alleles | GBS vs. healthy controls | Anti-GM1-Ab (positive vs. negative) |
|---------------|------------------|--------------------------|------------------------------------|
|               |                  | P-value | OR (95% CI)    | P-value | OR (95% CI)    |
| 1             | *0303-*0601-*0602 | 0.140   | 0.64 (0.36–1.16) | 0.184   | 0.58 (0.26–1.30) |
| 2             | *0301-*0303-*0602 | 1.00    | 1.0 (0.53–1.87)  | 0.581   | 1.23 (0.59–2.59) |
| 3             | *0201-*0302-*0602 | 0.529   | 1.22 (0.66–2.26) | 0.247   | 0.60 (0.26–1.42) |
| 4             | *0201-*0302-*0501 | 0.105   | 0.44 (0.16–1.19) | 0.265   | 0.43 (0.10–1.90) |
| 5             | *0501-*0602      | 0.265   | 0.65 (0.31–1.38) | 0.881   | 1.07 (0.44–2.60) |
| 6             | *0201-*0302      | 0.538   | 1.16 (0.72–1.89) | 0.498   | 0.81 (0.44–1.49) |
| 7             | *0201-*0302-*0303-*0601-*0602 | 0.006a | 0.49 (0.30–0.82) | 0.029b | 0.47 (0.24–0.93) |
| 8             | *0303-*0601      | 0.430   | 1.53 (0.53–4.41) | 0.467   | 0.57 (0.12–2.59) |

OR, Odds ratio; 95% CI, 95% confidence interval; Anti-GM1-Ab, anti-GM1 antibody seropositive or seronegative; aPc = 0.06 (Pc, P corrected); bPc = 0.29 (Pc, P corrected).
lost after correcting for multiple comparisons \( (P = 0.029, \text{OR} = 0.48, 95\% \text{ CI} = 0.25–0.92; \text{Pc} = 0.37; \text{Table 3} \). Haplotype 5 \((*0501-*0602)\) was significantly more prevalent in \(C.\ jejunii\) seropositive patients with the axonal variant compared to \(C.\ jejunii\) seropositive or seronegative patients with demyelinating subtype or unclassified GBS; but, this trend was not significant after Bonferroni correction \( (P = 0.024, \text{OR} = 4.06, 95\% \text{ CI} = 1.25–13.18; \text{Pc} = 0.24; \text{Table S1}) \). The \(DQB1*0401\) alleles were less frequent in \(C.\ jejunii\) seropositive patients with the axonal subtype than the \(C.\ jejunii\) seropositive or seronegative patients with other subtypes of GBS, but significance was lost after correcting for multiple comparisons \( (P = 0.045, \text{OR} = 0.39, 95\% \text{ CI} = 0.16–0.97; \text{Pc} = 0.58; \text{Table S1}) \).

**Figure 2.** Pairwise linkage disequilibrium (LD) among the 13 \(HLA-DQB1\) loci based on \(D'\) statistics. \(D' > 0.75\) indicated strong LD with white shade, \(D' 0.5–0.74\) indicated moderate LD with cyan shade, and \(D' < 0.49\) indicated weak LD with green shade. \(P\)-value overwrite above the respective LD where \(*** < 0.005, ** < 0.05, * < 0.01, \) Not significant \(> 0.1\).

**Association of HLA-DQB1 polymorphisms and haplotype variations with autoantibodies in patients with GBS**

The distribution of \(HLA-DQB1\) polymorphisms among antiganglioside antibody (Ab) seropositive patients with GBS is presented in Table S2. Overall, 48% \( (73/151) \) of patients with GBS were antiganglioside-Abseropositive: 38% \( (58/151) \) were anti-GM1-Abpositive, 15% \( (23/151) \) were anti-GD1a-Abpositive, and 9% \( (14/151) \) were anti-GQ1b-Abseropositive \( (Table\ S2) \). Among the anti-GM1-Abpositive patients, the frequency of the \(DQB1*0601\) allele was significantly lower in seropositive patients compared to seronegative patients, but this was not significant when the \(P\)-values were corrected for the number of
Alleles (*P* = 0.022, OR = 0.42, 95% CI = 0.20–0.88; *P* = 0.28; Table 5). Moreover, haplotype 9 (DQB1*0303-*0601) was less common among anti-GM1-Abs positive patients than seronegative patients, but this trend was not significant after correction (*P* = 0.029, OR = 0.47, 95% CI = 0.24–0.93; *P* = 0.29; Table 2).

**Association of HLA-DQB1 polymorphisms with severity and disease outcome in GBS**

The patients with GBS were classified as severely affected (74%) or mildly affected (26%) based on MRC sum score. The DQB1*0303 alleles were significantly more frequent among severely affected patients than mildly affected patients with GBS, but this significance was lost after correcting for multiple comparisons (*P* = 0.025, OR = 2.49; 95% CI, 1.13–5.48; *P* = 0.32; Table 6). However, no significant associations were observed between GBS disease severity and the 10 most common haplotype patterns. Furthermore, no significant associations were evident between the candidate alleles or haplotype patterns and disease outcome at 6 months of follow-up.

**Discussion**

This study investigated the association between DQB1 alleles and haplotype patterns and GBS susceptibility in Bangladesh. Associations between HLA complex genes and human autoimmune diseases have been described; however, studies of HLA typing among populations with different genetic backgrounds have reported inconclusive associations with GBS. In this study, we observed no association between DQB1 alleles or haplotype patterns and disease susceptibility to GBS; the DQB1 alleles and haplotype patterns had no influence on the clinical and serological subgroups of GBS in Bangladesh after the *P*-values were corrected.

GBS is a heterogeneous disorder with respect to severity, prognosis, and clinical features. In this study, the DQB1*0303 alleles were significantly associated with the severe form of GBS before correcting for multiple comparisons, implying that HLA-DQB1 polymorphisms may possibly influence disease severity and the extent of the inflammatory response at the peripheral nerves. Though a Dutch study reported no association between HLA-DQB1 alleles and disease severity, the HLA-DRB1*01 allele was associated with the need for mechanical ventilation in patients with GBS.14

The associations of individual HLA-DQB1 polymorphic alleles with GBS have been studied; however, haplotype studies were not performed. In this study, we found individual DQB1 alleles or haplotype were not associated with the development of GBS. However, haplotype 9 (HLA-DQB1*0601-*0303) was less frequent among patients with GBS in Bangladesh compared to healthy controls and LD analysis also indicated their association among DQB1 *0601 and *0303 alleles. Moreover, no significant LD was observed between the alleles of the 10 most common haplotype. This implies that the presence of both alleles (HLA-DQB1*0601-*0303) may exert a reciprocal effect toward the development of GBS in the Bangladeshi population.

The DQB1*03 allele is significantly associated with *C. jejuni* infection. However, our study revealed a relatively lower frequency of the DQB1*0303 and *0601 alleles and a slightly higher frequency of the *0502 alleles in *C. jejuni* seropositive patients compared to healthy controls. This discrepancy may be due to local evolutionary
pressure among infectious agents in different ethnic populations. A previous study also indicated the contribution of HLA-DQB1*030x alleles to regional variation in GBS.21 Further analysis revealed haplotype 5 (*0501-*0602) was more frequent in the C. jejuni-associated axonal variant of GBS compared to other subtypes of GBS. This observation may be one factor explaining the higher prevalence of the axonal subtype of GBS in Bangladesh compared to other regions of the world. Furthermore, this also may explain how human ancestry and race modify C. jejuni strain’s interaction with an individual’s immune system to trigger different subtypes of GBS.22 In our Bangladeshi population, a higher frequency of the DQB1*0201 allele was observed in the demyelinating variant of GBS.

### Table 4. Distribution of HLA-DQB1 polymorphic alleles in healthy controls and C. jejuni seropositive and C. jejuni seronegative patients with GBS.

| Allele | Healthy controls n = 151 (%) | C. jejuni seropositive n = 95 HC vs. Cj (+) | Axonal type | Demyelinating type |
|--------|-----------------------------|----------------------------------------------|-------------|--------------------|
|        | Allele                      | P-value | Odds ratio (95% CI) | n = 59 (57%) | n = 47 (80%) | n = 12 (20%) | n = 27 (26%) | n = 12 (44%) | n = 15 (56%) |
|        | DQB1*0201                  | 0.489   | 1.25 (0.73–2.15)    | 21 (36)     | 17           | 4            | 15 (55)     | 6           | 9          |
|        | DQB1*0301/4                | 0.348   | 0.73 (0.38–1.36)    | 14 (24)     | 9            | 5            | 6 (22)      | 2           | 4          |
|        | DQB1*0302                  | 0.357   | 0.77 (0.46–1.30)    | 23 (40)     | 16           | 7            | 15 (55)     | 6           | 9          |
|        | DQB1*0303                  | 0.066   | 0.60 (0.35–1.00)    | 25 (42)     | 20           | 5            | 11 (41)     | 4           | 7          |
|        | DQB1*0401                  | 0.329   | 1.38 (0.74–2.61)    | 11 (19)     | 7            | 4            | 8 (30)      | 3           | 5          |
|        | DQB1*0501                  | 0.96 (0.53–1.76) | 1.00               | 17 (29)     | 14           | 3            | 4 (15)      | 1           | 3          |
|        | DQB1*0502                  | 0.034*  | 0.34 (0.13–0.95)    | 3 (5)       | 3            | 0            | 1 (4)       | 0           | 1          |
|        | DQB1*0503                  | 0.436   | 1.36 (0.64–2.91)    | 6 (10)      | 5            | 1            | 4 (15)      | 3           | 1          |
|        | DQB1*0601                  | 0.033*  | 0.55 (0.33–0.94)    | 17 (29)     | 15           | 2            | 12 (44)     | 5           | 7          |
|        | DQB1*0602                  | 0.291   | 1.35 (0.80–2.28)    | 37 (63)     | 29           | 8            | 17 (63)     | 8           | 9          |
|        | DQB1*0603/8                | 1.00    | 1.06 (0.29–3.87)    | 2 (4)       | 2            | 0            | 0 (0)       | 0           | 0          |
|        | DQB1*0604                  | 1.00    | 0.79 (0.14–4.40)    | 0 (0)       | 0            | 0            | 1 (4)       | 1           | 0          |
|        | DQB1*0605                  | 0.710   | 0.63 (0.12–3.30)    | 0 (0)       | 0            | 0            | 2 (7)       | 1           | 1          |

**Note:** Cj, Campylobacter jejuni; sero+, C. jejuni seropositive; sero–, C. jejuni seronegative; HC, healthy control; 95% CI, 95% confidence interval; *Pc = 0.44 (Pc, P corrected); **Pc = 0.42 (Pc, P corrected).

### Table 5. Distribution of HLA-DQB1*060x polymorphisms within anti-GM1 antibody seropositive and seronegative patients with GBS.

| Presence of anti-GM1 antibody | Healthy controls n = 40 (% | Demyelinating type |
|-------------------------------|---------------------------|--------------------|
| Allele                        | Positive n = 58 (%)        | Mildly affected n = 111 (%) | Severely affected n = 40 (%) | P-value | Odds ratio (95% CI) |
| DQB1*0601                      | 13 (22)                    | 42 (38)            | 0.572               | 0.79 (0.36–1.69) |
| DQB1*0602                      | 37 (64)                    | 26 (23)            | 1.00                | 0.94 (0.40–2.24) |
| DQB1*0603/8                    | 0 (0)                      | 26 (23)            | 1.69                | 0.90 (0.42–2.16) |
| DQB1*0604                      | 11 (28)                    | 20 (18)            | 2.16                | 1.72 (0.74–4.02) |
| DQB1*0605                      | 12 (28)                    | 18 (15)            | 2.76                | 1.72 (0.74–4.02) |

95% CI, 95% confidence interval; nc, not calculated; *Pc = 0.28 (Pc, P corrected).

### Table 6. Distribution of HLA-DQB1 allele frequency among patients with different severities of GBS.

| Allele | Healthy controls n = 40 | Demyelinating type |
|--------|-------------------------|--------------------|
|        | Mildly affected n = 111 | P-value | Odds ratio (95% CI) |
|        | (%)                     | (95% CI)           |                    |
| DQB1*0201 | 13 (33) | 42 (38) | 0.572 | 0.79 (0.36–1.69) |
| DQB1*0301/4 | 9 (23) | 26 (23) | 1.00 | 0.94 (0.40–2.24) |
| DQB1*0302 | 18 (45) | 45 (41) | 0.709 | 1.2 (0.57–2.48) |
| DQB1*0303 | 11 (28) | 54 (49) | 0.025* | 2.49 (1.13–5.48) |
| DQB1*0401 | 10 (25) | 29 (26) | 1.00 | 0.94 (0.41–2.16) |
| DQB1*0501 | 11 (28) | 20 (18) | 0.253 | 1.72 (0.74–4.02) |
| DQB1*0502 | 2 (5) | 11 (10) | 0.515 | 0.47 (0.10–2.25) |
| DQB1*0503 | 3 (8) | 17 (15) | 0.281 | 0.44 (0.12–1.62) |
| DQB1*0601 | 10 (25) | 40 (36) | 0.243 | 0.59 (0.26–1.34) |
| DQB1*0602 | 24 (60) | 64 (58) | 0.853 | 1.10 (0.52–2.30) |
| DQB1*0603/8 | 2 (5) | 5 (5) | 1.00 | 1.12 (0.21–5.99) |
| DQB1*0604 | 2 (5) | 1 (1) | 0.171 | 5.78 (0.51–65.67) |
| DQB1*0605 | 1 (3) | 3 (3) | 1.00 | 0.92 (0.09–9.13) |

Mildly affected at nadir, MRC sum score ≥ 40; severely affected at nadir, MRC sum score < 40; 95% CI, 95% confidence interval; *Pc = 0.32 (Pc, P corrected).

However, it is important to confirm and compare our results with studies of other ethnic populations from different regions of the world where the demyelinating variant of GBS predominates.

Campylobacter jejuni-triggered GBS is frequently associated with anti-GM1 antibodies, and GM1 acts as a target pathogenic antigen that triggers the axonal variant of...
GBS.27,32 HLA class II genes are recognized by CD4+ Th cells and are known to influence antibody responses by activating B cells.33 A previous study observed no association between HLA alleles and the presence of anti-GM1 antibodies. However, the HLA-DRB1*0803 and HLA-DQA1*0301 alleles were more frequent in Japanese34 and Chinese30 anti-GM1 antibody-positive patients with GBS, respectively, while no significant association was observed between the HLA-DRB1 and HLA-DQB1 alleles and anti-GM1 antibody positivity in Dutch patients with GBS.14 We did not observe a significant association between HLA-DQB1 alleles and anti-GM1 antibody positivity in Bangladeshi GBS patients.

HLA-DQB1 alleles have diverse effects on susceptibility to autoimmune diseases. A stronger association between the DQB1*06 alleles and disease susceptibility and a lower frequency of the DQB1*03 alleles were observed in multiple sclerosis.35 Similar studies on HLA-DQB1 polymorphisms showed a higher risk of type I diabetes among individuals with the DQB1*0201/*0302 alleles, whereas the DQB1*0301, DQB1*0601,*DQB1*0602, DQB1*0603, and DQB1*05 alleles protect against the development of type I diabetes.36 Furthermore, the DQB1*04 alleles confer susceptibility to rheumatoid arthritis, whereas the DQB1*06 alleles protect against the development of rheumatoid arthritis.37

This study has several limitations. Even though we used one of the largest GBS cohorts from developing countries, the sample size was relatively small for investigation of a large number of haplotypes in GBS patients. Here, we only explored the association of HLA-DQB1 alleles with disease susceptibility and subgroups, without considering other HLA alleles that are also important in GBS pathogenesis.

In conclusion, HLA-DQB1 gene polymorphisms and haplotype were not associated with susceptibility to GBS in the Bangladeshi population. However, the importance of HLA-DQB1 polymorphisms in the pathogenesis of GBS still remains unclear. Extensive analysis of a larger cohort of patients (e.g. from the IGOS study)25 from various ethnic backgrounds is required to confirm our findings on HLA-DQB1 alleles and haplotype and the development and progression of GBS.

Acknowledgments

This research activity was funded by the icddr,b, Dhaka, Bangladesh. The icddr,b acknowledges with gratitude the commitment of the Government of Bangladesh to its research efforts, and also gratefully acknowledges the Governments of the People’s Republic of Bangladesh, Canada, Sweden, and the UK who provide unrestricted support. We are also indebted to the neurologists who referred their patients to us.

Author Contributions

ZI and SH conceived and designed the study. SH and IJ contributed to data acquisition. SH, IJ, and AD performed data analysis and interpreted the data. ZI and SH drafted the manuscript, which was critically reviewed by IJ, AD, ZH, ZHH, IM, and QDM for intellectual content. All authors read and approved the final manuscript before submission.

Conflict of Interest

The authors do not have any conflict of interest to report.

References

1. Luppi P, Licata A, Haluszczak C, et al. Analysis of TCR Vβ repertoire and cytokine gene expression in patients with idiopathic dilated cardiomyopathy. J Autoimmun 2001;16:3–13.
2. Winer JB. Guillain Barré syndrome. Mol Pathol 2001;54:381–385.
3. Wim Ang C, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004;25:61–66.
4. Islam Z, Gilbert M, Mohammad QD, et al. Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies. PLoS ONE 2012;7:43976.
5. Rose NR. Negative selection, epitope mimicry and autoimmunity. Curr Opin Immunol 2017;49:51–55.
6. Nachamkin I. Campylobacter enteritis and the Guillain-Barré syndrome. Curr Infect Dis Rep 2001;3:116–122.
7. Tauxe RV. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. Campylobacter jejuni: Curr Status Futur Trends 1992; 9–19.
8. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001;15:397–408.
9. Marsh SGE. HLA class II region sequences, 1998. Tissue Antigens 2008;51:467–507.
10. Kappes D, Strominger JL. Human class II major histocompatibility complex genes and proteins. Annu Rev Biochem 1988;57:991–1028.
11. Shiina T, Inoko H, Kulski JK. An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 2004;64:631–649.
12. Janeway CA, Travers, P. Antigen recognition by T lymphocytes. 3rd ed. Immunobiology: pp. 41–46. New York and London: Garland Publishing, 1997.
13. Klein J, Sato A. The HLA system. N Engl J Med 2000;343:782–786.
14. Geleijns K, Schreuder G, Neurology BJ, et al. HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome. AAN Enterp 2005;11:44–49.
S. Hayat et al.

HLA-DQB1 Polymorphisms and Haplotype in GBS

15. Sinha S, Prasad KN, Jain D, et al. Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome. Acta Neurol Scand 2010;122:21–26.
16. Rees JH, Vaughan RW, Kondeatis E, Hughes RA. HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol 1995;62:53–57.
17. Koga M, Yuki N, Kashiwase K, et al. Guillain-Barré and Fisher’s syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies. J Neuroimmunol 1998;88:62–66.
18. Magira EE, Papaioakim M, Nachamkin I, et al. Differential distribution of HLA-DQB/DRB3 epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating. Am Assoc Immnol 2003;170:3074–3080.
19. Ashbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:S21–S24.
20. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597–605.
21. Hadden RDM, Cornblath DR, Hughes RAC, et al. Electrophysiological classification of guillain-barré syndrome: clinical associations and outcome. Ann Neurol 2005;44:780–788.
22. Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barré syndrome: A critical revision and the need for an update. Clin Neurophysiol 2012;123:1487–1495.
23. Kleyweg RP, Van Der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103–1109.
24. Gelejns K, Emonts M, Laman JD, et al. Genetic polymorphisms of macrophage mediators in Guillain-Barré syndrome. J Neuroimmunol 2007;190:127–130.
25. Jacobs BC, van den Berg B, Verboon C, et al. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst 2017;22:68–76.
26. Kuijfl ML, van Doorn PA, Tio-Gillen AP, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005;239:37–44.
27. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 2010;74:581–587.
28. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993;41:119–134.
29. Olerup O, Zetterquist H. HLA-DRB101 subtyping by allele-specific PCR amplification: A sensitive, specific and rapid technique. Tissue Antigens 1991;37:197–204.
30. Li H, Yuan J, Hao H, et al. HLA alleles in patients with Guillain-Barré syndrome. Chin Med J 2000;113:429–432.
31. Jin PP, Sun LL, Ding BJ, et al. Human leukocyte antigen DQB1 (HLA-DQB1) polymorphisms and the risk for Guillain-Barré syndrome: a systematic review and meta-analysis. PLoS ONE 2015;10:e0131374.
32. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990;40:1900–1902.
33. Simmonds M, Gough S. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics 2007;8:453–465.
34. Ma JJ, Nishimura M, Minesh H, et al. HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome. Neurology 1998;51:379–384.
35. Michalik J, Cierny D, Kantorova E, et al. The association of HLA-DRB1 and HLA-DQB1 alleles with genetic susceptibility to multiple sclerosis in the Slovak population. Neurol Res 2015;37:1060–1067.
36. Guja C, Guja L, Nutland S, et al. Type 1 diabetes genetic susceptibility encoded by HLA DQB1 genes in Romania. J Cell Mol Med 2004;8:249–256.
37. Wu J, Li J, Li S, et al. Association of HLA-DQB1 polymorphisms with rheumatoid arthritis: a meta-analysis. Postgrad Med J 2017;93:618–625.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Association studies of axonal subtype patients with antiganglioside antibodies, HLA-DQB1 alleles, haplotype, and LOS.

Table S2. Distribution of HLA-DQB1 alleles in antiganglioside antibody-seropositive patients with GBS and in healthy controls.